(Atovaquone + proguanil hydrochloride) is under clinical development by IPCA Laboratories and currently in Phase I for Malaria. According to GlobalData, Phase I drugs for Malaria have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Atovaquone + proguanil hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Atovaquone + proguanil hydrochloride) overview
Atoguanil (atovaquone in fixed dose combination with proguanil hydrochloride) is under development for the treatment of malaria. It is administered as tablet. It is developed based on proprietary Ipca technology.
IPCA Laboratories overview
IPCA Laboratories (IPCA) is a manufacturer and supplier of active pharmaceutical ingredients (APIs), and branded formulations. The company has API manufacturing facilities located in Madhya Pradesh, Maharashtra, Gujarat, Andhra Pradesh, Sunderland, and North Carolina. It runs formulation facilities in Silvassa, Madhya Pradesh, Maharashtra, Uttaranchal, Sikkim, and Gujarat among others. The company manufactures over 350 formulations and 80 APIs for various therapeutic segments. It offers products for pain, rheumatology, antimalarials and hair care therapy. The company markets its products across the Americas, Africa, Asia, Australia, and Europe. IPCA is headquartered in Mumbai, Maharashtra, India.
For a complete picture of (Atovaquone + proguanil hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.